Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPPOEM: Routine vs Symptomatic PPI Post-POEM for Achalasia
NCT05899842Recruiting
- Sponsor
- CHU Nîmes
- Start
- Jun 2023
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of lansoprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by CHU Nîmes. Primary endpoint: Presence of pathological acid reflux at 12 months. Started Jun 2023; status: recruiting.
02
Drugs
lansoprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05899842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05899842.